BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a report released on Sunday morning. The firm issued a sell rating on the medical technology company’s stock.

BIOLASE Price Performance

BIOL opened at $0.01 on Friday. The business has a 50 day moving average price of $0.01 and a two-hundred day moving average price of $0.01. The company has a market capitalization of $457,675.90, a price-to-earnings ratio of 0.00 and a beta of 0.67. BIOLASE has a 1-year low of $0.02 and a 1-year high of $1.94.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.